Compare NBP & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBP | USNA |
|---|---|---|
| Founded | 2014 | 1992 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.2M | 317.0M |
| IPO Year | N/A | 1996 |
| Metric | NBP | USNA |
|---|---|---|
| Price | $2.41 | $18.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 87.3K |
| Earning Date | 04-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.58 |
| Revenue | N/A | ★ $1,060,902,000.00 |
| Revenue This Year | N/A | $3.90 |
| Revenue Next Year | N/A | $6.21 |
| P/E Ratio | ★ N/A | $33.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $16.60 |
| 52 Week High | $5.19 | $38.32 |
| Indicator | NBP | USNA |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 47.41 |
| Support Level | $2.27 | $16.70 |
| Resistance Level | $2.78 | $21.21 |
| Average True Range (ATR) | 0.14 | 0.73 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 21.05 | 10.23 |
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.